AOD 9064 5 mg

AOD 9064, also known as AOD-9604, is a modified fragment of human growth hormone (hGH), specifically the C-terminal 16 amino acids. This peptide has been studied for its potential lipolytic (fat-burning) effects without influencing blood sugar levels or stimulating growth hormone release.

AOD9604 Research

AOD9604 and Obesity

AOD9604 was initially developed as an analogue of human growth hormone (HGH) specifically aimed at reducing fat. Phase 2b clinical trials conducted in Australia involved 300 obese participants. Results from once-daily administration of the peptide over 12 weeks demonstrated that AOD9604 tripled weight loss compared to placebo, with the rate of weight loss remaining consistent throughout the trial. This steady effect suggests that resistance to the peptide is unlikely, and longer-term treatment may result in even greater weight loss.

Mouse studies with genetically obese models indicate that AOD9604 likely does not act solely through beta-3-adrenergic receptors found on white adipose tissue. Initially, it was believed that the peptide bound these receptors to increase fat cell metabolism, shifting fat from storage to usage. However, fat loss still occurred in mice lacking these receptors, implying that additional mechanisms are involved. One theory suggests that AOD9604 may indirectly induce apoptosis in white fat cells.

Joint Pain and Function

Research in rat models shows that intra-articular injections of AOD9604 into arthritic joints can synergize with existing therapies to alleviate pain, reduce disability, and improve quality of life. Both gross clinical examination and microscopic analysis of cartilage indicate that AOD9604 effectively targets the root causes of osteoarthritis and may serve as both treatment and prevention. While effective alone, AOD9604 demonstrates enhanced benefits when combined with other treatments. The precise mechanisms behind this synergy remain unclear, but further research could uncover novel pathways to promote cartilage regeneration—an especially challenging clinical issue.

AOD9604 and Heart Disease

Beyond fat reduction and weight loss, which directly decrease cardiovascular risk, evidence suggests that AOD9604 benefits heart health independently of its effects on adiposity. It is proposed that the peptide influences metabolism in ways that reduce complications separate from obesity management. This phenomenon is analogous to drugs like pioglitazone and acipimox, which improve metabolic outcomes without directly addressing obesity. The secondary fat loss pathway of AOD9604, independent of beta-3-adrenergic receptor activation, may also contribute to improved metabolic parameters.

Research Applications

AOD 9064 is utilized in scientific studies focusing on:

• Fat Metabolism: Investigating its role in stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage).
• Weight Management: Assessing its potential in reducing body fat and improving body composition.
• Regenerative Medicine: Studying its effects on cartilage and joint health.

Product Specifications

• Form: Lyophilized (freeze-dried) powder for reconstitution.
• Dosage: Each vial contains 5 mg of AOD 9064.
• Purity: ≥99%, ensuring high-quality material for research purposes.
• Packaging: Sealed vials to maintain product integrity.
• Storage: Store in a cool, dry place away from direct sunlight. After reconstitution, store at 4°C and use within 2-7 days.

Safety and Handling

AOD 9064 is intended strictly for laboratory research and is not approved for human consumption. Handle with care, following appropriate safety protocols. Ensure proper storage conditions to maintain the integrity and efficacy of the compound.

Referenced Citations

• F.M. Ng, J. Sun, L. Sharma, R. Libinaka, W.J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. 
• H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7–15, Apr. 2013. 
• “Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. [Online]. Available: [Accessed: 24-May-2019]. 
• R. Zieba, “[Obesity: a review of currently used anti-obesity drugs and new compounds in clinical development],” Postepy Hig. Med. Doswiadczalne Online, vol. 61, pp. 612–626, Oct. 2007. 
• M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. 
• D.R. Kwon and G.Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015. 
• M.D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 1435–1495, Jun. 2006. 
• H. Stier, E. Vos, D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” Journal of Endocrinology and Metabolism, North America, vol. 3, Apr. 2013.